Methylene Blue Dosage Chart: Clinical Context for Precision Treatment Planning

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Methylene blue dosage ranges from 0.5 to 2 mg/kg for clinical applications, but optimal dosing depends on indication, renal function, and individual metabolic factors. FDA-labeled uses and off-label applications carry distinct dosing protocols that require qualified provider evaluation.

Understanding methylene blue dosing in context matters because it reflects a broader principle: precision medicine relies on patient-specific factors, not one-size-fits-all protocols. At PlexusDx, we recognize that personalized treatment planning—whether for metabolic compounds or other therapies—benefits from both clinical evidence and individual biomarker context.

Indication-Specific Dosing and FDA Label Context

FDA-approved methylene blue indications include treatment of methemoglobinemia and cyanide poisoning, with distinct dosing protocols. For methemoglobinemia, intravenous dosing typically ranges 1–2 mg/kg, while cyanide poisoning protocols involve different administration routes and concentrations based on severity.

Off-label uses—including cognitive support and mitochondrial enhancement—lack FDA-established dosing and require evidence review and provider judgment. Clinical literature suggests 15–300 mg daily oral dosing for these applications, but variability reflects small studies and heterogeneous patient populations. Provider oversight remains essential.

Dosage Ranges Across Clinical Applications and Patient Factors

Methylene blue dosing is not linear; it depends on route of administration, clinical goal, renal function, and concomitant medications. The table below outlines commonly referenced dosage frameworks and key variables that influence provider dosing decisions.

Clinical Context	Typical Dosage Range	Key Variables	Provider Oversight
Methemoglobinemia (IV)	1–2 mg/kg IV bolus	Severity, renal function, repeat dosing	Required for all cases
Cyanide poisoning (IV)	4–5 mg/kg IV infusion	Body weight, poison exposure route, ICU setting	Critical care setting only
Cognitive/mitochondrial (oral)	15–300 mg daily	Age, kidney function, drug interactions, symptom response	Strongly recommended
Urinary tract symptoms (oral)	50–100 mg twice daily	Renal clearance, symptom severity, treatment duration	Baseline and monitoring assessment

Renal Function, Drug Interactions, and Dosage Adjustment

Methylene blue undergoes hepatic and renal metabolism. Patients with reduced glomerular filtration rate, chronic kidney disease, or hepatic impairment may accumulate the compound, necessitating dose reduction or extended dosing intervals. Provider assessment of baseline renal and hepatic function is standard practice.

Concomitant medications—including serotonergic agents, MAOIs, and certain antibiotics—interact with methylene blue and increase serotonin syndrome risk. These drug interactions may warrant dose adjustment, alternative sequencing, or avoidance. A complete medication review with your provider prevents adverse interactions.

Safety Considerations, Monitoring, and Who Should Use Methylene Blue

Methylene blue is contraindicated in G6PD deficiency, severe renal impairment without dialysis access, and pregnancy (especially first trimester). Relative cautions include breastfeeding, serotonin syndrome risk, and photosensitivity. Pre-treatment screening includes metabolic panel, G6PD status where indicated, and drug interaction review.

Adverse effects include nausea, abdominal pain, headache, and rare cases of serotonin syndrome or methemoglobinemia (paradoxically, at high doses). Dosing decisions require baseline assessment and periodic monitoring. Patients considering methylene blue should initiate care through a qualified provider familiar with both FDA-labeled and evidence-based off-label protocols.

How PlexusDx Supports a More Personalized Approach

Precision dosing principles extend across therapeutic domains. At PlexusDx, our Precision Peptide Genetic Test reveals predispositions in metabolic and receptor pathways—including variants in FTO, MC4R, and GLP-1R genes—that may help provide context for how individuals metabolize compounds and respond to dose adjustments. These insights can support more informed conversations with providers about personalization.

The genetic test identifies predispositions, not exact medication response predictions. For methylene blue or other compounds, genetic variants may correlate with metabolic efficiency or drug-handling capacity, but clinical phenotype, age, renal function, and lifestyle factors ultimately drive dosing decisions. Genetic context should always be interpreted with a qualified healthcare provider.

Understanding your biomarker and genetic profile may help you ask better questions of your provider about why a particular dose might be chosen for you, whether adjustments are likely, and what monitoring matters most. PlexusDx encourages precision conversations between patients and clinicians—grounded in evidence and individual biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the standard methylene blue dose for acute methemoglobinemia?

FDA-labeled dosing is 1–2 mg/kg intravenous bolus, repeated once after 5–60 minutes if methemoglobin levels remain elevated. Dosing depends on body weight, severity, and renal function. Acute methemoglobinemia is a medical emergency and requires immediate hospital care.

Can methylene blue be taken orally, and what is a typical oral dose?

Yes; oral methylene blue is available for off-label uses. Clinical literature suggests 15–300 mg daily divided doses, but evidence is limited. Oral dosing carries different absorption kinetics than intravenous and lacks standardized FDA protocols. Provider guidance is essential for oral use.

How do kidney problems affect methylene blue dosing?

Reduced renal clearance increases methylene blue accumulation. Patients with eGFR below 30 mL/min/1.73m² typically require dose reduction or extended intervals. Baseline kidney function assessment and periodic monitoring are standard. Dialysis access affects dosing decisions.

What interactions does methylene blue have with common medications?

Methylene blue interacts with serotonergic drugs (SSRIs, MAOIs, tramadol), certain antibiotics, and anticoagulants. These interactions may increase serotonin syndrome risk or bleeding. A complete medication review with your provider before starting methylene blue is essential.

Can genetic testing predict how I'll tolerate or respond to methylene blue dosing?

The Precision Peptide Genetic Test identifies predispositions in metabolic pathways, but does not predict exact methylene blue response. Genetic variants in detoxification or receptor genes may inform provider dosing discussions, but clinical assessment, renal function, and drug interactions drive the actual decision.